We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

FAPON

Fapon is a global IVD raw materials & one-stop solutions company offering 700+ reagent raw materials for the applicat... read more Featured Products: More products

Download Mobile App





Fapon Presents AI-Driven Diagnostic Innovation and Advanced Alzheimer's Disease Blood Testing Solutions

By LabMedica International staff writers
Posted on 18 Nov 2025

Fapon, a global leader in life sciences, is participating at MEDICA 2025 from November 17 to 20 in Düsseldorf, Germany, where it is underscoring its strengths in diagnostic innovation. More...

At booth A81 in Hall 3, the company is presenting how AI-driven technologies are advancing diagnostic R&D and unveiling a range of IVD solutions and new products, with particular emphasis on its state-of-the-art blood testing solutions for Alzheimer’s disease (AD).

Fapon’s “AI-driven + closed-loop dry and wet experimentation” R&D model greatly enhances the efficiency of biomarker discovery and the development of diagnostic solutions. A standout achievement of this approach is the company’s advanced AD blood testing solution. Designed to support IVD manufacturers, it offers a complete suite of raw materials and bulk reagents for core Alzheimer’s biomarkers, including p-tau 217, p-tau 181, amyloid beta 40, amyloid beta 42, GFAP, NfL, and APOE4. These innovative materials deliver high sensitivity and specificity, with strong concordance to predicate kits and established clinical tests, enabling the development of more precise and reliable AD assays.

Fapon is also presenting its full suite of one-stop IVD solutions, encompassing raw materials, reagent development services, and open-platform instruments. A highlight is the chemiluminescence one-stop solution, which integrates high-performance core materials, a panel of more than 70 self-developed assays, and the versatile Shine i-Series CLIA analyzers encompassing low to ultra-high throughput to address testing demands across diverse clinical settings. Additionally, the Shine mT8000 Fully Automatic Clinical Chemistry and Immunoassay System provides end-to-end workflow automation within a compact, space-efficient footprint of just 5 m².

Fapon is also showcasing its portfolio of high-performance IVD raw materials, including recombinant quality-control and calibrator components for key disease markers such as RF, HbA1c, HIV/HIV-P24, HCV, TP, HBV, and ToRCH. The company is further highlighting its animal-origin-free IgG blockers and LAMP solutions designed for rapid molecular testing.

Related Links:
Fapon Biotech


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Chromogenic Culture System
InTray™ COLOREX™ ECC
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.